USFDA has started inspecting carefully the generic facility in India and China. After opening the offices in China, USFDA is all set to establish their offices in India. Also, Pharmabiz has reported that US regulatory agency has commenced surprise inspections of all its approved facilities in India. In India there are more than 110 USFDA approved plants.
Recently, some senate members and NGO's in US are criticizing FDA for not using adeqate measures to check flow of substandard generics from Asia.
No comments:
Post a Comment